{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:24:36Z","timestamp":1790357076953,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Inostics GmbH"},{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) holds promise for guiding immune checkpoint inhibitor (ICI) therapy and stratifying responders from non-responders. While tumor-informed ctDNA detection approaches are sensitive and mutation-inclusive, they require tumor tissue, which limits applicability in real-world settings. Conversely, tumor-agnostic methods often have limited genomic coverage. In this study, we evaluated a tumor-agnostic, broad-panel ctDNA assay in patients with advanced melanoma treated with ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective analysis of 241 longitudinal samples from 39 patients with unresectable stage III\/IV melanoma using a SYSMEX targeted NGS panel covering 1,114 COSMIC mutations. Plasma samples were collected at baseline and during ICI therapy. The assay\u2019s sensitivity reached seven mutant molecules, corresponding to a 0.07% mutation allele frequency (MAF). ctDNA profiles were compared with matched tumor tissue and correlated with clinical features and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, ctDNA was detected in 64.5% of patients. Common mutations included\n                      <jats:italic>BRAF<\/jats:italic>\n                      <jats:sup>V600E<\/jats:sup>\n                      (43.8%) and\n                      <jats:italic>NRAS<\/jats:italic>\n                      <jats:sup>G12D<\/jats:sup>\n                      (36.4%), followed by\n                      <jats:italic>KRAS, EGFR,<\/jats:italic>\n                      and\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      variants. Overall tissue\u2013plasma concordance was 51.6%, with more extended biopsy\u2013plasma intervals associated with discordance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0105). Notably, 12.2% of cases exhibited partial concordance, characterized by shared mutations and additional plasma-only alterations, underscoring the complementary value of blood-based profiling. Persistent or re-emerging ctDNA positivity post-therapy correlated with shorter progression-free survival (PFS,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), while ctDNA-negative patients showed significantly improved outcomes. Patients that remained ctDNA-negative had significantly longer progression-free survival (median not reached) compared to those with persistent ctDNA positivity (median 3\u00a0months) or those converting to positive (median 7.5\u00a0months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0073). Early\n                      <jats:italic>NRAS<\/jats:italic>\n                      and\n                      <jats:italic>KRAS<\/jats:italic>\n                      ctDNA levels strongly predicted poor response (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0069 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028). The prognostic impact extended beyond canonical drivers, as non-hotspot variants also correlated with the outcome. Notably, even low-level ctDNA persistence (5\u201310 MM\/mL) carried adverse prognostic implications (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0054). Concerning a shorter PFS, ctDNA positivity was also associated with elevated S100 levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). Organ-specific mutation enrichment (e.g., KRAS\n                      <jats:sup>G12D<\/jats:sup>\n                      in brain, EGFR\n                      <jats:sup>G719A<\/jats:sup>\n                      in lymph nodes) suggested possible metastatic tropism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Broad tumor-agnostic ctDNA analysis effectively identified clinically relevant mutations and predicted outcomes in ICI-treated melanoma patients. This approach enables tissue-independent and real-time ctDNA monitoring and may inform patient selection and therapeutic strategies in future interventional trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03457-w","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T04:17:07Z","timestamp":1752293827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition"],"prefix":"10.1186","volume":"44","author":[{"given":"Isabel","family":"Heidrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rautmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Geidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"R\u00fcnger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Hansen-Abeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Abeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"3457_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010225","author":"X Wang","year":"2025","unstructured":"Wang X, Ma S, Zhu S, Zhu L, Guo W. Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13010225.","journal-title":"Biomedicines"},{"key":"3457_CR2","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"3457_CR3","doi-asserted-by":"publisher","unstructured":"Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, u.\u00a0a. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy\u2606. Ann Oncol. 2020; https:\/\/doi.org\/10.1016\/j.annonc.2020.04.471","DOI":"10.1016\/j.annonc.2020.04.471"},{"key":"3457_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03322-w5","author":"S Sheriff","year":"2025","unstructured":"Sheriff S, Saba M, Patel R, et al. A scoping review of factors influencing the implementation of liquid biopsy for cancer care. J Exp Clin Cancer Res. 2025.\u00a0https:\/\/doi.org\/10.1186\/s13046-025-03322-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"3457_CR5","doi-asserted-by":"publisher","unstructured":"Gebhardt C, Keller L, Heidrich I, et al. Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. JCO 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9562.","DOI":"10.1200\/JCO.2023.41.16_suppl.9562"},{"key":"3457_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102788","author":"E De Simoni","year":"2024","unstructured":"De Simoni E, Spagnolo F, Gandini S, Gaeta A, Rizzetto G, Molinelli E, Simonetti O, Offidani A, Queirolo P. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma. Cancer Treat Rev. 2024. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102788.","journal-title":"Cancer Treat Rev"},{"key":"3457_CR7","doi-asserted-by":"publisher","unstructured":"Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, u.\u00a0a. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023; =https:\/\/doi.org\/10.1038\/s41586-023-05776-4","DOI":"10.1038\/s41586-023-05776-4"},{"key":"3457_CR8","doi-asserted-by":"publisher","unstructured":"Takai E, Omata W, Totoki Y, Nakamura H, Shiba S, Takahashi A, u.\u00a0a. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Cancer Sci. 2021; https:\/\/doi.org\/10.1111\/cas.15088","DOI":"10.1111\/cas.15088"},{"key":"3457_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52923-0","author":"C Schroeder","year":"2024","unstructured":"Schroeder C, Gatidis S, Kelemen O, et al. Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-52923-0.","journal-title":"Nat Commun"},{"key":"3457_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02445-1","author":"JC Thompson","year":"2023","unstructured":"Thompson JC, Scholes DG, Carpenter EL, Aggarwal C. Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. Br J Cancer. 2023. https:\/\/doi.org\/10.1038\/s41416-023-02445-1.","journal-title":"Br J Cancer"},{"key":"3457_CR11","doi-asserted-by":"publisher","unstructured":"Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, u.\u00a0a. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer 2023; https:\/\/doi.org\/10.1136\/jitc-2022-005344","DOI":"10.1136\/jitc-2022-005344"},{"key":"3457_CR12","doi-asserted-by":"publisher","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, Mattos-Arruda LD, Diehn M, u.\u00a0a. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology 2022; https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520","DOI":"10.1016\/j.annonc.2022.05.520"},{"key":"3457_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020861","author":"C Mart\u00ednez-Vila","year":"2025","unstructured":"Mart\u00ednez-Vila C, Teixido C, Aya F, Mart\u00edn R, Gonz\u00e1lez-Navarro EA, Alos L, Castrejon N, Arance A. Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26020861.","journal-title":"Int J Mol Sci"},{"key":"3457_CR14","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S117121","author":"E Mu\u00f1oz-Couselo","year":"2017","unstructured":"Mu\u00f1oz-Couselo E, Adelantado EZ, Ortiz C, Garc\u00eda JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017. https:\/\/doi.org\/10.2147\/OTT.S117121.","journal-title":"Onco Targets Ther"},{"key":"3457_CR15","doi-asserted-by":"publisher","unstructured":"Koulouridi A, Karagianni M, Messaritakis I, Sfakianaki M, Voutsina A, Trypaki M, u.\u00a0a. Prognostic Value of KRAS Mutations in Colorectal Cancer Patients. Cancers (Basel) 2022; https:\/\/doi.org\/10.3390\/cancers14143320","DOI":"10.3390\/cancers14143320"},{"key":"3457_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00827-6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021. https:\/\/doi.org\/10.1038\/s41392-021-00827-6.","journal-title":"Signal Transduct Target Ther"},{"key":"3457_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030540","author":"A Forschner","year":"2020","unstructured":"Forschner A, Hilke FJ, Bonzheim I, et al. MDM2, MDM4 and EGFR Amplifications and\u00a0Hyperprogression in Metastatic Acral and Mucosal Melanoma. Cancers (Basel). 2020.\u00a0https:\/\/doi.org\/10.3390\/cancers12030540.","journal-title":"Cancers (Basel)"},{"key":"3457_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11062-2","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, et al. Whole-genome landscape of mucosal melanoma\u00a0reveals diverse drivers and therapeutic targets. Nat Commun. 2019.\u00a0https:\/\/doi.org\/10.1038\/s41467-019-11107-x.","journal-title":"Nat Commun"},{"key":"3457_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.015","author":"DS Tan","year":"2021","unstructured":"Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung\u00a0Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non\u2013Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016.\u00a0https:\/\/doi.org\/10.1016\/j.jtho.2016.05.008.","journal-title":"J Thorac Oncol"},{"key":"3457_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.03.001","author":"BO Van Emburgh","year":"2014","unstructured":"Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, et al. Acquired resistance to\u00a0EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014.\u00a0https:\/\/doi.org\/10.1016\/j.molonc.2014.05.003.","journal-title":"Mol Oncol"},{"key":"3457_CR21","doi-asserted-by":"publisher","unstructured":"Pietraszek-Gremplewicz K, Simiczyjew A, Dratkiewicz E, Podg\u00f3rska M, Stycze\u0144 I, Matkowski R, u.\u00a0a. Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells. Journal of Cellular and Molecular Medicine. 2019; https:\/\/doi.org\/10.1111\/jcmm.14730","DOI":"10.1111\/jcmm.14730"},{"key":"3457_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06112-1","author":"J Mirek","year":"2024","unstructured":"Mirek J, Bal W, Olbryt M. Melanoma genomics \u2013 will we go beyond BRAF in clinics?. J Cancer Res Clin Oncol. 2024. https:\/\/doi.org\/10.1007\/s00432-025-06112-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3457_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030590","author":"S Candido","year":"2022","unstructured":"Candido S, Salemi R, Piccinin S, Falzone L, Libra M. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14030590.","journal-title":"Pharmaceutics"},{"key":"3457_CR24","doi-asserted-by":"publisher","unstructured":"Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, u.\u00a0a. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4\/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discov. 2018; https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0745","DOI":"10.1158\/2159-8290.CD-17-0745"},{"key":"3457_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/nature13948","author":"D Juric","year":"2015","unstructured":"Juric D, Castel P, Griffith M, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature. 2015. https:\/\/doi.org\/10.1038\/nature13948.","journal-title":"Nature"},{"key":"3457_CR26","doi-asserted-by":"publisher","unstructured":"Schroeder C, Gatidis S, Kelemen O, Sch\u00fctz L, Bonzheim I, Muyas F, u.\u00a0a. Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition. Nat Commun. 2024; https:\/\/doi.org\/10.1038\/s41467-024-52923-0","DOI":"10.1038\/s41467-024-52923-0"},{"key":"3457_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1520441","author":"L Liu","year":"2025","unstructured":"Liu L, Hou S, Zhu A, Yan B, Li L, Song D. The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2024.1520441.","journal-title":"Front Immunol"},{"key":"3457_CR28","doi-asserted-by":"publisher","unstructured":"Boerlin A, Bellini E, Turko P, Cheng PF, Levesque MP, Dummer R, u.\u00a0a. The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma. Cancers (Basel) 2022; https:\/\/doi.org\/10.3390\/cancers14174158","DOI":"10.3390\/cancers14174158"},{"key":"3457_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061197","author":"R Pikturniene","year":"2024","unstructured":"Pikturniene R, Cesas A, Jarmalaite S, Razbadauskas A, Urbonas V. Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16061197.","journal-title":"Cancers"},{"key":"3457_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13357","author":"J Wu","year":"2023","unstructured":"Wu J, Liu Z, Huang T, Wang Y, Song MM, Song T, Long G, Zhang X, Li X, Zhang L. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC. Mol Oncol. 2023. https:\/\/doi.org\/10.1002\/1878-0261.13357.","journal-title":"Mol Onco"},{"key":"3457_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2025.04.007","author":"AM Chahardehi","year":"2025","unstructured":"Chahardehi AM, Faraji N, Emtiazi N, Nasiri R, Daghagheleh M, Mohammadaein H, et al. The emerging role of circulating tumor DNA in brain tumor research. IBRO Neurosci Rep. 2025. https:\/\/doi.org\/10.1016\/j.ibneur.2025.04.007.","journal-title":"IBRO Neurosci Rep"},{"key":"3457_CR32","doi-asserted-by":"publisher","unstructured":"Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, u.\u00a0a. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Molecular Oncology 2015; https:\/\/doi.org\/10.1016\/j.molonc.2014.12.003","DOI":"10.1016\/j.molonc.2014.12.003"},{"key":"3457_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.089","author":"A Bayle","year":"2022","unstructured":"Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, et al. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). Ann Oncol. 2022. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.089.","journal-title":"Ann Oncol"},{"key":"3457_CR34","doi-asserted-by":"publisher","unstructured":"Lasse-Opsahl EL, Barravecchia I, McLintock E, et al. KRASG12D drives immunosuppression in lung adenocarcinoma through paracrine signaling. JCI Insight. 2025. https:\/\/doi.org\/10.1172\/jci.insight.182228.","DOI":"10.1172\/jci.insight.182228"},{"key":"3457_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030398","author":"F Pereira","year":"2022","unstructured":"Pereira F, Ferreira A, Reis CA, Sousa MJ, Oliveira MJ, Preto A. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11030398.","journal-title":"Cells"},{"key":"3457_CR36","doi-asserted-by":"publisher","unstructured":"Eichholz J, Gaeta B, Walch H, Boe L, Kratochvil L, Balzo LA del, u.\u00a0a. The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. 2023; https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.871","DOI":"10.1016\/j.ijrobp.2023.06.871"},{"key":"3457_CR37","doi-asserted-by":"publisher","unstructured":"Jour G, Illa-Bochaca I, Ibrahim M, Donnelly D, Zhu K, Miera EVS de, u.\u00a0a. Genomic and Transcriptomic Analyses ofNF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment. Journal of Investigative Dermatology 2023; https:\/\/doi.org\/10.1016\/j.jid.2022.07.022","DOI":"10.1016\/j.jid.2022.07.022"},{"key":"3457_CR38","doi-asserted-by":"publisher","unstructured":"Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, u.\u00a0a. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumor origin and respond favorably to immune-checkpoint inhibitors. Eur J Cancer 2021; https:\/\/doi.org\/10.1016\/j.ejca.2021.09.035","DOI":"10.1016\/j.ejca.2021.09.035"},{"key":"3457_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146477","author":"FT Rad","year":"2022","unstructured":"Rad FT, Gargari BN, Ghorbian S, Farsani ZS, Sharifi R. Inhibiting the growth of melanoma cells via hTERT gene editing using CRISPR-dCas9-dnmt3a system. Gene. 2022. https:\/\/doi.org\/10.1016\/j.gene.2022.146477.","journal-title":"Gene"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03457-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03457-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:51:34Z","timestamp":1788763894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03457-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3457"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03457-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: minor corrections were made in some of the reference details","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involves human participants, and the local ethics committee of the Hamburg Medical Association approved the study (PV5392). All participants provided informed consent before inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IH has received honoraria from BMS and Sysmex for lectures and presentations outside the submitted work. SWS has received honoraria from GSK, Leo, Sanofi, Pfizer, Almirall, and Novartis. SWS is a board member of the Hiege Stiftung \u2013 Die Deutsche Hautkrebsstiftung, unpaid. JK received grants from Hiege-Stiftung \u2013 Die Deutsche Hautkrebsstiftung, Roggenbuck-Stiftung, UCCH-fellowship, and MSNZ, outside the submitted work. GG received honoraria from Almirall Hermal GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, and Janssen-Cilag GmbH for lectures and presentations. CG is a board member of the Hiege Stiftung \u2013 Die Deutsche Hautkrebsstiftung, unpaid. CG has research support from BMS, Novartis, Pierre-Fabre, Regeneron, and Sanofi. CG is a member of the advisory board of BioNTech, BMS, Immunocore, MSD, Novartis, Pierre-Fabre, Regeneron, Sanofi, SUN Pharma, and Sysmex. CG has received honoraria from BMS, GSK, Immunocore, MSD, Novartis, Pierre Fabre, Regeneron, Sanofi, Sun Pharma, and Sysmex. KP has received funding from the EU\/IHI (GUIDE.MRD).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"202"}}